Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood.
This report aims to provide a comprehensive presentation of the global market for Immune Thrombocytopenia Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immune Thrombocytopenia Drugs. This report contains market size and forecasts of Immune Thrombocytopenia Drugs in global, including the following market information:
- Global Immune Thrombocytopenia Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
- Global top five companies in 2022 (%)
The global Immune Thrombocytopenia Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
End-users prefer biosimilars over biologics because of their low cost. The low cost of biosimilars can be attributed to the fewer number of clinical trials required for approval. The upcoming expiration of patents in the immune thrombocytopenia drugs market will fuel the development of biosimilars for those products. For instance, the forthcoming expiration of patents of Nplate (romiplostim) and rituximab has encouraged market vendors to develop their biosimilars. This will also create several opportunities for new vendors to enter the market. Hence, the growing popularity and development of biosimilars will augment the growth of the immune thrombocytopenia drugs market throughout the next five years.
We surveyed the Immune Thrombocytopenia Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Immune Thrombocytopenia Drugs Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Immune Thrombocytopenia Drugs Market Segment Percentages, by Type, 2022 (%)
- Thrombopoietin Receptor Agonists (TPO-RAs)
- Corticosteroids
- Intravenous Immunoglobins (IVIGs)
- Other Drugs
Global Immune Thrombocytopenia Drugs Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Immune Thrombocytopenia Drugs Market Segment Percentages, by Application, 2022 (%)
- Biotechnology and Pharmaceutical Companies
- Hospitals and Diagnostic Centers
- Academic Institutes and Research Organizations
Global Immune Thrombocytopenia Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Immune Thrombocytopenia Drugs Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Immune Thrombocytopenia Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Immune Thrombocytopenia Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Amgen Inc.
- CSL Ltd.
- Horizon Therapeutics Plc
- Merck & Co., Inc.
- Novartis AG
- Rigel Pharmaceuticals Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Immune Thrombocytopenia Drugs, market overview.
Chapter 2: Global Immune Thrombocytopenia Drugs market size in revenue.
Chapter 3: Detailed analysis of Immune Thrombocytopenia Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Immune Thrombocytopenia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
